Medicine – Myotonic Dystrophy

Myotonic dystrophy, also called dystrophia myotonica, is an inherited multisystem disorder characterised by myotonia, progressive muscle weakness and wasting, cataracts, endocrine abnormalities, cardiac conduction disease, and characteristic facial features.

It is usually inherited in an autosomal dominant pattern.

1. Inheritance

Myotonic dystrophy is classically autosomal dominant.

The commonest form, myotonic dystrophy type 1 (DM1), is caused by expansion of a CTG trinucleotide repeat in the DMPK gene.

The number of repeats can increase when passed from one generation to the next, producing anticipation.

Anticipation means that the disease may appear earlier and more severely in successive generations.

2. Myotonia

Myotonia means delayed relaxation of skeletal muscle after voluntary contraction.

For example, a patient may tightly grip an examiner’s hand but then have difficulty releasing it promptly.

Therefore:

Muscle contracts normally → relaxation is delayed.

This is one of the defining features of myotonic dystrophy.

3. Percussion Myotonia

Myotonia can also be demonstrated by percussion.

Tapping certain muscles, such as the thenar muscles, may produce a prolonged contraction before relaxation.

This is called percussion myotonia.

4. Myotonic Facies

Patients may develop a characteristic appearance known as myotonic facies.

This results from weakness and wasting of the facial and temporal muscles.

Typical features include:

Long, thin face.

Temporal wasting.

Hollowed cheeks.

Weak facial expression.

Ptosis.

The overall appearance may become quite distinctive in established disease.

5. Bilateral Ptosis

Bilateral ptosis is common because of weakness of the muscles that elevate the upper eyelids.

Unlike myasthenia gravis, the ptosis is generally more persistent and occurs alongside other characteristic muscular and systemic features.

6. Facial Muscle Weakness

Weakness of facial muscles may cause:

Reduced facial expression.

Difficulty closing the eyes tightly.

Weakness of smiling or whistling.

Difficulty with speech or swallowing in advanced disease.

Muscle wasting around the temples and jaw contributes to the characteristic facial appearance.

7. Frontal Balding

Premature frontal balding, especially in men, is a classic associated feature.

It is not caused simply by muscle weakness but forms part of the multisystem phenotype of the disorder.

Thus, an examination combination such as:

Myotonia + frontal balding + cataracts + distal weakness

should strongly suggest myotonic dystrophy.

8. Pattern of Muscle Weakness

Muscle weakness is usually progressive.

In classic DM1, weakness often begins predominantly in the distal muscles, particularly:

Hand muscles.

Forearm muscles.

Ankle dorsiflexors.

Over time, more proximal muscle groups may become affected.

9. Muscle Wasting

Progressive weakness is accompanied by muscle wasting.

Commonly affected regions include:

Distal limbs.

Facial muscles.

Temporal muscles.

Sternocleidomastoid muscles.

Advanced disease can therefore produce substantial functional impairment.

10. Cataracts

Cataracts are a classic extramuscular manifestation.

A characteristic appearance is the so-called Christmas-tree cataract, which contains brightly coloured, iridescent lens opacities.

Not every patient has this exact appearance, but early cataract formation is strongly associated with myotonic dystrophy.

11. Insulin Resistance

Patients may develop insulin resistance and other metabolic abnormalities.

This may lead to impaired glucose tolerance or diabetes mellitus.

Insulin resistance is part of the broader endocrine involvement seen in myotonic dystrophy.

12. Other Endocrine Features

Other endocrine and reproductive abnormalities may occur.

These can include:

Testicular atrophy.

Reduced fertility.

Hypogonadism.

Thyroid dysfunction in some patients.

The disorder therefore affects much more than skeletal muscle.

13. Cardiac Involvement

An important feature not included in the original note is cardiac conduction disease.

Patients may develop:

PR prolongation.

Bundle branch block.

Atrioventricular block.

Atrial or ventricular arrhythmias.

Because conduction abnormalities can cause syncope or sudden cardiac death, cardiac surveillance is an important part of management.

14. Respiratory Involvement

Respiratory muscles can also become weak.

In addition, patients may have impaired central respiratory drive or sleep-disordered breathing.

Consequences can include:

Nocturnal hypoventilation.

Sleep apnoea.

Daytime somnolence.

Respiratory failure in advanced disease.

15. Gastrointestinal Involvement

Smooth-muscle dysfunction may affect the gastrointestinal tract.

Patients may develop:

Dysphagia.

Gastro-oesophageal reflux.

Constipation.

Intestinal dysmotility.

These features reinforce the fact that myotonic dystrophy is a multisystem disorder, not simply a muscular disease.

16. Myotonic Dystrophy Type 1 and Type 2

There are two major forms.

Myotonic dystrophy type 1 (DM1) is the classic form and is associated with CTG repeat expansion in the DMPK gene.

DM1 more commonly produces distal weakness, facial weakness, myotonia, cataracts, and potentially congenital disease.

Myotonic dystrophy type 2 (DM2) is caused by a different repeat expansion and often produces more proximal muscle weakness and pain.

The phenotype can overlap considerably with DM1.

17. Congenital Myotonic Dystrophy

Severe DM1 can occasionally present at birth as congenital myotonic dystrophy.

Affected infants may have:

Severe hypotonia.

Respiratory weakness.

Feeding difficulties.

Delayed motor development.

Congenital disease is particularly associated with maternal transmission.

18. Diagnosis

Diagnosis is usually confirmed by genetic testing.

For DM1, testing identifies an expanded CTG repeat in the DMPK gene.

Electromyography may also show characteristic myotonic discharges.

These are often described as having a waxing-and-waning sound resembling a “dive bomber,” although this description is mainly an examination teaching aid.

19. Management

There is no universal curative treatment, so management is largely multidisciplinary and supportive.

Important areas include:

Physiotherapy and rehabilitation.

Cardiac monitoring.

Respiratory assessment.

Treatment of cataracts.

Management of endocrine abnormalities.

Genetic counselling.

20. Treatment of Myotonia

Myotonia does not always require drug treatment.

If it is functionally troublesome, medications such as mexiletine may be used under specialist supervision.

Treatment is aimed at improving muscle relaxation rather than reversing the underlying genetic disorder.

21. Cardiac Surveillance

Patients require regular assessment for conduction abnormalities.

This may include:

ECG.

Ambulatory rhythm monitoring when indicated.

Cardiology review.

Some patients eventually require a pacemaker or implantable cardiac device depending on the conduction disturbance and arrhythmia risk.

22. Cataract Management

Cataracts are treated in the usual way when they become visually significant.

This generally involves cataract extraction with intraocular lens implantation.

Because cataracts may occur relatively early, visual symptoms should be actively assessed.

23. Myotonic Dystrophy – Note Form

Inheritance: autosomal dominant.

Classic mutation: CTG repeat expansion in the DMPK gene in DM1.

Anticipation: disease may become earlier and more severe in successive generations.

Myotonia: delayed relaxation after muscle contraction.

Myotonic facies: long thin face, temporal wasting, facial weakness and ptosis.

Ptosis: usually bilateral.

Frontal balding: classic associated feature.

Muscle weakness: progressive and classically distal in DM1.

Muscle wasting: affects distal limbs, facial muscles, temporal muscles and sternocleidomastoids.

Cataracts: common; Christmas-tree cataracts are characteristic.

Metabolic feature: insulin resistance.

Cardiac complication: conduction defects and arrhythmias.

Respiratory complication: respiratory muscle weakness and sleep-related hypoventilation.

Diagnosis: genetic testing ± EMG showing myotonic discharges.

Key Clinical Pattern

Remember myotonic dystrophy as:

Autosomal dominant + myotonia + distal muscle weakness + frontal balding + bilateral ptosis + cataracts + insulin resistance.

The most characteristic examination clue is:

Patient grips strongly but cannot relax the hand promptly.

And the major systemic complication to remember is:

Myotonic dystrophy → cardiac conduction disease and arrhythmias.

Medicine – Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that produces fluctuating, fatigable weakness of voluntary skeletal muscle. Weakness typically becomes worse with repeated activity and improves after rest.

The disease commonly affects the ocular, bulbar, limb, and respiratory muscles, while sensation and tendon reflexes are usually preserved.

1. Pathophysiology

In most patients, the immune system produces antibodies directed against components of the postsynaptic membrane of the neuromuscular junction.

The commonest antibodies are directed against the nicotinic acetylcholine receptor (AChR).

These antibodies reduce effective neuromuscular transmission by decreasing the number and function of available acetylcholine receptors and damaging the postsynaptic membrane.

2. Neuromuscular Junction Mechanism

Normally, acetylcholine is released from the presynaptic motor nerve terminal and binds to acetylcholine receptors on the muscle membrane.

This generates an end-plate potential and triggers muscle contraction.

In myasthenia gravis:

AChR antibodies → fewer functional postsynaptic acetylcholine receptors → reduced neuromuscular transmission → fatigable muscle weakness.

With repeated activity, neuromuscular transmission becomes progressively less effective, explaining the characteristic fatigability.

3. Other Antibodies

Not all patients have acetylcholine-receptor antibodies.

Some have antibodies against other postsynaptic proteins, particularly:

MuSK – muscle-specific kinase.

LRP4 – low-density lipoprotein receptor-related protein 4.

Therefore, a negative acetylcholine-receptor antibody test does not completely exclude myasthenia gravis.

4. Fatigable Weakness

The hallmark of MG is fluctuating weakness that worsens with repeated activity and improves with rest.

Patients may feel relatively strong in the morning but become weaker later in the day or after repeatedly using the same muscle group.

This contrasts with Lambert–Eaton myasthenic syndrome, in which strength may temporarily improve after brief exercise.

5. Ptosis

Ptosis is one of the most common presenting features.

It may be unilateral or bilateral and often fluctuates.

A characteristic feature is that the ptosis may become more obvious when the patient is asked to maintain prolonged upward gaze.

After resting or closing the eyes, the ptosis may improve.

6. Ophthalmoplegia

Weakness of the extraocular muscles can produce:

Diplopia.

Variable ophthalmoplegia.

The pattern may change during examination because different ocular muscles fatigue at different rates.

Importantly, pupillary function is preserved in myasthenia gravis because the pupil is controlled by autonomic smooth muscle rather than skeletal muscle.

Thus:

Ptosis + ophthalmoplegia + normal pupils → consider myasthenia gravis.

7. Bulbar Weakness

Muscles involved in speech, swallowing, and facial movement may become affected.

Patients may develop:

Dysarthria.

Dysphagia.

Nasal speech.

Difficulty chewing.

Facial weakness.

Speech may become progressively weaker or more nasal after prolonged talking.

8. Limb Weakness

Limb involvement generally produces proximal greater than distal weakness.

Patients may have difficulty:

Climbing stairs.

Getting up from a chair.

Lifting objects above the head.

Combing their hair.

The weakness fluctuates and becomes more pronounced after repeated muscular activity.

9. Sensation and Reflexes

Sensation is normally intact in myasthenia gravis.

Deep tendon reflexes are also generally preserved.

This is useful when distinguishing MG from conditions such as Lambert–Eaton syndrome, where tendon reflexes are commonly reduced.

10. Respiratory Muscle Weakness

Respiratory muscle involvement is potentially life-threatening.

Weakness of the diaphragm and other respiratory muscles can cause ventilatory failure.

Severe respiratory weakness in a patient with myasthenia gravis is known as a myasthenic crisis.

This requires urgent assessment and often intensive respiratory monitoring.

11. Myasthenic Crisis

A myasthenic crisis is severe worsening of MG resulting in respiratory insufficiency and/or severe bulbar weakness.

Common triggers include:

Infection.

Surgery.

Medication changes.

Pregnancy or physiological stress.

Certain drugs that impair neuromuscular transmission.

Patients may require ventilatory support and specialist treatment with intravenous immunoglobulin or plasma exchange.

12. Acetylcholine-Receptor Antibodies

Blood testing for AChR antibodies is an important diagnostic investigation.

The old figure of approximately 90% needs qualification.

AChR antibodies are found in the great majority of patients with generalised MG, but sensitivity is lower in purely ocular disease.

Therefore:

Positive AChR antibodies strongly support the diagnosis, but negative antibodies do not exclude MG.

13. MuSK Antibodies

Patients who are negative for AChR antibodies may be tested for MuSK antibodies.

MuSK-positive MG can particularly involve:

Bulbar muscles.

Facial muscles.

Neck muscles.

Respiratory muscles.

The clinical phenotype and treatment response can differ somewhat from classic AChR-positive disease.

14. Electromyography

Electrophysiological testing assesses the reliability of neuromuscular transmission.

With repetitive nerve stimulation, patients with MG typically show a decremental response in the compound muscle action potential.

In simple terms:

Repeated stimulation → progressively smaller muscle response.

This reflects failure of neuromuscular transmission.

15. Single-Fibre EMG

Single-fibre electromyography is particularly sensitive for detecting impaired neuromuscular transmission.

It demonstrates increased variability in the timing of muscle-fibre activation, called increased jitter.

It is useful when routine investigations are inconclusive but clinical suspicion remains high.

16. Edrophonium – Tensilon Test

Historically, the Tensilon test used intravenous edrophonium, a very short-acting acetylcholinesterase inhibitor.

By inhibiting acetylcholinesterase, edrophonium temporarily increased acetylcholine at the neuromuscular junction.

A patient with MG could therefore show rapid temporary improvement in weakness.

The mechanism was:

Edrophonium → acetylcholinesterase inhibition → ↑ acetylcholine → improved neuromuscular transmission → temporary improvement in weakness.

17. Tensilon Test in Modern Practice

The Tensilon test is now largely historical and is not routinely used in many modern clinical settings because edrophonium can cause significant adverse effects, including bradycardia and other cardiovascular complications.

Modern diagnosis relies more heavily on:

Antibody testing.

Repetitive nerve stimulation.

Single-fibre EMG.

Clinical bedside assessment remains important.

18. Ice-Pack Test

For patients with prominent ptosis, the ice-pack test can provide useful bedside evidence.

An ice pack is placed over the closed eyelid for a few minutes.

Improvement in ptosis after cooling supports a diagnosis of myasthenia gravis because lower temperatures can improve neuromuscular transmission.

It is particularly useful in ocular MG.

19. Thymus Association

Myasthenia gravis has an important relationship with the thymus gland.

Patients may have:

Thymic hyperplasia.

or

Thymoma.

The thymus is believed to play an important role in generating the abnormal autoimmune response in many patients with AChR-positive MG.

20. CT Thorax

Patients with newly diagnosed MG are generally evaluated for a thymoma, commonly using CT imaging of the chest.

Therefore:

Myasthenia gravis → image the mediastinum to exclude thymoma.

This association is particularly important for examinations.

21. Pyridostigmine

Pyridostigmine is a commonly used symptomatic treatment.

It is an acetylcholinesterase inhibitor.

By reducing the breakdown of acetylcholine, it increases the amount of acetylcholine available at the neuromuscular junction.

The mechanism is:

Acetylcholinesterase inhibition → ↑ acetylcholine in synaptic cleft → improved activation of remaining ACh receptors → improved strength.

22. Limitations of Pyridostigmine

Pyridostigmine improves symptoms but does not remove the underlying autoimmune process.

Adverse effects arise mainly from excess cholinergic activity and may include:

Abdominal cramps.

Diarrhoea.

Increased salivation.

Sweating.

Muscle fasciculations in excessive doses.

23. Corticosteroids

Corticosteroids, such as prednisolone, are frequently used when symptomatic therapy alone is insufficient.

They suppress the autoimmune response and can substantially improve muscle strength.

Because steroids can occasionally cause transient worsening when first introduced, initiation and dose escalation may require careful specialist supervision in patients with significant bulbar or respiratory involvement.

24. Other Immunosuppressive Treatments

Additional steroid-sparing immunosuppressive drugs may be used for long-term disease control.

Examples include:

Azathioprine.

Mycophenolate mofetil.

Other immunotherapies, including targeted biologic agents, are increasingly used for selected patients with refractory or severe disease.

25. Thymectomy

Thymectomy is indicated when a thymoma is present, provided the patient is an appropriate surgical candidate.

Thymectomy can also improve outcomes in selected patients with generalised AChR-antibody-positive MG even without thymoma.

Therefore, thymectomy is not simply a treatment for thymoma; in appropriately selected patients it can modify the course of autoimmune MG itself.

26. Plasma Exchange

Plasma exchange removes circulating pathogenic antibodies and can produce relatively rapid improvement.

It is particularly useful in:

Myasthenic crisis.

Severe exacerbations.

Preparation for surgery in selected high-risk patients.

Its effects occur rapidly but are relatively short-lived.

27. Intravenous Immunoglobulin

Intravenous immunoglobulin (IVIG) is another rapid immunomodulatory treatment.

It is commonly used for:

Myasthenic crisis.

Severe exacerbations.

Situations where rapid improvement is required.

Like plasma exchange, it is primarily used for relatively rapid short-term disease control rather than routine symptomatic therapy.

28. Drugs That Can Worsen Myasthenia

Certain medications can impair neuromuscular transmission and worsen MG.

Important examples include some:

Aminoglycoside antibiotics.

Fluoroquinolones.

Macrolides.

Magnesium-containing preparations.

Beta-blockers.

Neuromuscular-blocking drugs used during anaesthesia.

Medication decisions depend on clinical circumstances, but patients with MG should have potentially aggravating drugs reviewed carefully.

29. Myasthenia Gravis versus Lambert–Eaton Syndrome

Myasthenia gravis:

Postsynaptic disorder.

Usually antibodies against ACh receptors.

Weakness worsens with repeated activity.

Ocular symptoms are common.

Reflexes generally preserved.

Autonomic symptoms are uncommon.

Associated with thymic hyperplasia or thymoma.

Lambert–Eaton syndrome:

Presynaptic disorder.

Antibodies against voltage-gated calcium channels.

Weakness may improve temporarily with brief exercise.

Proximal lower-limb weakness is prominent.

Reflexes reduced.

Autonomic symptoms common.

Strongly associated with small-cell lung carcinoma.

30. Myasthenia Gravis – Note Form

Definition: autoimmune neuromuscular-junction disorder causing fluctuating, fatigable skeletal-muscle weakness.

Main antibody: postsynaptic acetylcholine-receptor antibody.

Other antibodies: MuSK and LRP4.

Ptosis: common, fluctuating and worsens with prolonged upward gaze.

Ophthalmoplegia: causes diplopia; pupils remain normal.

Bulbar involvement: dysarthria, dysphagia, nasal speech and chewing fatigue.

Weakness: worsens with repeated activity and improves with rest.

Sensation: normal.

Reflexes: usually normal.

Respiratory involvement: can cause life-threatening myasthenic crisis.

Antibody testing: AChR antibodies are highly useful, particularly in generalised MG.

EMG: decremental response with repetitive nerve stimulation.

Single-fibre EMG: increased jitter and high sensitivity.

Tensilon test: historical edrophonium test; rapid improvement occurred after short-acting acetylcholinesterase inhibition, but it is now rarely used.

Thoracic imaging: performed to look for thymoma.

Symptomatic treatment: pyridostigmine.

Immunotherapy: corticosteroids and other immunosuppressive treatments.

Thymectomy: mandatory consideration with thymoma and beneficial in selected generalised AChR-positive patients without thymoma.

Severe exacerbation/crisis: IVIG or plasma exchange ± ventilatory support.

Key Clinical Pattern

Remember myasthenia gravis as:

Ptosis + diplopia + bulbar weakness + fatigable skeletal-muscle weakness that worsens with repeated activity.

The neurological examination typically shows:

Weak muscles + normal sensation + preserved reflexes + normal pupils.

The core mechanism is:

Postsynaptic ACh-receptor antibodies → impaired neuromuscular transmission.

The key association is:

Myasthenia gravis → thymoma/thymic abnormalities.

And the easiest comparison remains:

MG → weakness worsens with activity.

LEMS → weakness initially improves with activity.

1. Pathophysiology In most patients, the immune system produces antibodies directed against components of the postsynaptic membrane of the neuromuscular junction. The commonest antibodies are directed against the nicotinic acetylcholine receptor (AChR). These antibodies reduce effective neuromuscular transmission by decreasing the number and function of available acetylcholine receptors and damaging the postsynaptic membrane. 

2. Neuromuscular Junction Mechanism Normally, acetylcholine is released from the presynaptic motor nerve terminal and binds to acetylcholine receptors on the muscle membrane. This generates an end-plate potential and triggers muscle contraction. In myasthenia gravis: AChR antibodies → fewer functional postsynaptic acetylcholine receptors → reduced neuromuscular transmission → fatigable muscle weakness. With repeated activity, neuromuscular transmission becomes progressively less effective, explaining the characteristic fatigability. 

3. Other Antibodies Not all patients have acetylcholine-receptor antibodies. Some have antibodies against other postsynaptic proteins, particularly: MuSK – muscle-specific kinase. LRP4 – low-density lipoprotein receptor-related protein 4. Therefore, a negative acetylcholine-receptor antibody test does not completely exclude myasthenia gravis. 

4. Fatigable Weakness The hallmark of MG is fluctuating weakness that worsens with repeated activity and improves with rest. Patients may feel relatively strong in the morning but become weaker later in the day or after repeatedly using the same muscle group. This contrasts with Lambert–Eaton myasthenic syndrome, in which strength may temporarily improve after brief exercise. 

5. Ptosis Ptosis is one of the most common presenting features. It may be unilateral or bilateral and often fluctuates. A characteristic feature is that the ptosis may become more obvious when the patient is asked to maintain prolonged upward gaze. After resting or closing the eyes, the ptosis may improve. 

6. Ophthalmoplegia Weakness of the extraocular muscles can produce: Diplopia. Variable ophthalmoplegia. The pattern may change during examination because different ocular muscles fatigue at different rates. Importantly, pupillary function is preserved in myasthenia gravis because the pupil is controlled by autonomic smooth muscle rather than skeletal muscle. Thus: Ptosis + ophthalmoplegia + normal pupils → consider myasthenia gravis. 

7. Bulbar Weakness Muscles involved in speech, swallowing, and facial movement may become affected. Patients may develop: Dysarthria. Dysphagia. Nasal speech. Difficulty chewing. Facial weakness. Speech may become progressively weaker or more nasal after prolonged talking. 

8. Limb Weakness Limb involvement generally produces proximal greater than distal weakness. Patients may have difficulty: Climbing stairs. Getting up from a chair. Lifting objects above the head. Combing their hair. The weakness fluctuates and becomes more pronounced after repeated muscular activity. 

9. Sensation and Reflexes Sensation is normally intact in myasthenia gravis. Deep tendon reflexes are also generally preserved. This is useful when distinguishing MG from conditions such as Lambert–Eaton syndrome, where tendon reflexes are commonly reduced. 

10. Respiratory Muscle Weakness Respiratory muscle involvement is potentially life-threatening. Weakness of the diaphragm and other respiratory muscles can cause ventilatory failure. Severe respiratory weakness in a patient with myasthenia gravis is known as a myasthenic crisis. This requires urgent assessment and often intensive respiratory monitoring. 

11. Myasthenic Crisis A myasthenic crisis is severe worsening of MG resulting in respiratory insufficiency and/or severe bulbar weakness. Common triggers include: Infection. Surgery. Medication changes. Pregnancy or physiological stress. Certain drugs that impair neuromuscular transmission. Patients may require ventilatory support and specialist treatment with intravenous immunoglobulin or plasma exchange. 

12. Acetylcholine-Receptor Antibodies Blood testing for AChR antibodies is an important diagnostic investigation. The old figure of approximately 90% needs qualification. AChR antibodies are found in the great majority of patients with generalised MG, but sensitivity is lower in purely ocular disease. Therefore: Positive AChR antibodies strongly support the diagnosis, but negative antibodies do not exclude MG. 

13. MuSK Antibodies Patients who are negative for AChR antibodies may be tested for MuSK antibodies. MuSK-positive MG can particularly involve: Bulbar muscles. Facial muscles. Neck muscles. Respiratory muscles. The clinical phenotype and treatment response can differ somewhat from classic AChR-positive disease. 

14. Electromyography Electrophysiological testing assesses the reliability of neuromuscular transmission. With repetitive nerve stimulation, patients with MG typically show a decremental response in the compound muscle action potential. In simple terms: Repeated stimulation → progressively smaller muscle response. This reflects failure of neuromuscular transmission. 

15. Single-Fibre EMG Single-fibre electromyography is particularly sensitive for detecting impaired neuromuscular transmission. It demonstrates increased variability in the timing of muscle-fibre activation, called increased jitter. It is useful when routine investigations are inconclusive but clinical suspicion remains high. 

16. Edrophonium – Tensilon Test Historically, the Tensilon test used intravenous edrophonium, a very short-acting acetylcholinesterase inhibitor. By inhibiting acetylcholinesterase, edrophonium temporarily increased acetylcholine at the neuromuscular junction. A patient with MG could therefore show rapid temporary improvement in weakness. The mechanism was: Edrophonium → acetylcholinesterase inhibition → ↑ acetylcholine → improved neuromuscular transmission → temporary improvement in weakness. 

17. Tensilon Test in Modern Practice The Tensilon test is now largely historical and is not routinely used in many modern clinical settings because edrophonium can cause significant adverse effects, including bradycardia and other cardiovascular complications. Modern diagnosis relies more heavily on: Antibody testing. Repetitive nerve stimulation. Single-fibre EMG. Clinical bedside assessment remains important. 

18. Ice-Pack Test For patients with prominent ptosis, the ice-pack test can provide useful bedside evidence. An ice pack is placed over the closed eyelid for a few minutes. Improvement in ptosis after cooling supports a diagnosis of myasthenia gravis because lower temperatures can improve neuromuscular transmission. It is particularly useful in ocular MG. 

19. Thymus Association Myasthenia gravis has an important relationship with the thymus gland. Patients may have: Thymic hyperplasia. or Thymoma. The thymus is believed to play an important role in generating the abnormal autoimmune response in many patients with AChR-positive MG. 

20. CT Thorax Patients with newly diagnosed MG are generally evaluated for a thymoma, commonly using CT imaging of the chest. Therefore: Myasthenia gravis → image the mediastinum to exclude thymoma. This association is particularly important for examinations. 

21. Pyridostigmine Pyridostigmine is a commonly used symptomatic treatment. It is an acetylcholinesterase inhibitor. By reducing the breakdown of acetylcholine, it increases the amount of acetylcholine available at the neuromuscular junction. The mechanism is: Acetylcholinesterase inhibition → ↑ acetylcholine in synaptic cleft → improved activation of remaining ACh receptors → improved strength. 

22. Limitations of Pyridostigmine Pyridostigmine improves symptoms but does not remove the underlying autoimmune process. Adverse effects arise mainly from excess cholinergic activity and may include: Abdominal cramps. Diarrhoea. Increased salivation. Sweating. Muscle fasciculations in excessive doses. 

23. Corticosteroids Corticosteroids, such as prednisolone, are frequently used when symptomatic therapy alone is insufficient. They suppress the autoimmune response and can substantially improve muscle strength. Because steroids can occasionally cause transient worsening when first introduced, initiation and dose escalation may require careful specialist supervision in patients with significant bulbar or respiratory involvement. 

24. Other Immunosuppressive Treatments Additional steroid-sparing immunosuppressive drugs may be used for long-term disease control. Examples include: Azathioprine. Mycophenolate mofetil. Other immunotherapies, including targeted biologic agents, are increasingly used for selected patients with refractory or severe disease. 

25. Thymectomy Thymectomy is indicated when a thymoma is present, provided the patient is an appropriate surgical candidate. Thymectomy can also improve outcomes in selected patients with generalised AChR-antibody-positive MG even without thymoma. Therefore, thymectomy is not simply a treatment for thymoma; in appropriately selected patients it can modify the course of autoimmune MG itself. 

26. Plasma Exchange Plasma exchange removes circulating pathogenic antibodies and can produce relatively rapid improvement. It is particularly useful in: Myasthenic crisis. Severe exacerbations. Preparation for surgery in selected high-risk patients. Its effects occur rapidly but are relatively short-lived. 

27. Intravenous Immunoglobulin Intravenous immunoglobulin (IVIG) is another rapid immunomodulatory treatment. It is commonly used for: Myasthenic crisis. Severe exacerbations. Situations where rapid improvement is required. Like plasma exchange, it is primarily used for relatively rapid short-term disease control rather than routine symptomatic therapy. 

28. Drugs That Can Worsen Myasthenia Certain medications can impair neuromuscular transmission and worsen MG. Important examples include some: Aminoglycoside antibiotics. Fluoroquinolones. Macrolides. Magnesium-containing preparations. Beta-blockers. Neuromuscular-blocking drugs used during anaesthesia. Medication decisions depend on clinical circumstances, but patients with MG should have potentially aggravating drugs reviewed carefully. 

29. Myasthenia Gravis versus Lambert–Eaton Syndrome Myasthenia gravis: Postsynaptic disorder. Usually antibodies against ACh receptors. Weakness worsens with repeated activity. Ocular symptoms are common. Reflexes generally preserved. Autonomic symptoms are uncommon. Associated with thymic hyperplasia or thymoma. 

Lambert–Eaton syndrome: Presynaptic disorder. Antibodies against voltage-gated calcium channels. Weakness may improve temporarily with brief exercise. Proximal lower-limb weakness is prominent. Reflexes reduced. Autonomic symptoms common. Strongly associated with small-cell lung carcinoma. 

30. Myasthenia Gravis – Note Form Definition: autoimmune neuromuscular-junction disorder causing fluctuating, fatigable skeletal-muscle weakness. 

Main antibody: postsynaptic acetylcholine-receptor antibody. 

Other antibodies: MuSK and LRP4. 

Ptosis: common, fluctuating and worsens with prolonged upward gaze. 

Ophthalmoplegia: causes diplopia; pupils remain normal. 

Bulbar involvement: dysarthria, dysphagia, nasal speech and chewing fatigue. 

Weakness: worsens with repeated activity and improves with rest. 

Sensation: normal. 

Reflexes: usually normal. 

Respiratory involvement: can cause life-threatening myasthenic crisis. 

Antibody testing: AChR antibodies are highly useful, particularly in generalised MG. 

EMG: decremental response with repetitive nerve stimulation. 

Single-fibre EMG: increased jitter and high sensitivity. 

Tensilon test: historical edrophonium test; rapid improvement occurred after short-acting acetylcholinesterase inhibition, but it is now rarely used. 

Thoracic imaging: performed to look for thymoma. 

Symptomatic treatment: pyridostigmine. 

Immunotherapy: corticosteroids and other immunosuppressive treatments. 

Thymectomy: mandatory consideration with thymoma and beneficial in selected generalised AChR-positive patients without thymoma. 

Severe exacerbation/crisis: IVIG or plasma exchange ± ventilatory support. 

Key Clinical Pattern Remember myasthenia gravis as: Ptosis + diplopia + bulbar weakness + fatigable skeletal-muscle weakness that worsens with repeated activity. The neurological examination typically shows: Weak muscles + normal sensation + preserved reflexes + normal pupils. The core mechanism is: Postsynaptic ACh-receptor antibodies → impaired neuromuscular transmission. The key association is: Myasthenia gravis → thymoma/thymic abnormalities. And the easiest comparison remains: MG → weakness worsens with activity. LEMS → weakness initially improves with activity.

Medicine – Lambert–Eaton Myasthenic Syndrome

Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the presynaptic neuromuscular junction. It causes impaired release of acetylcholine from motor nerve terminals and therefore produces characteristic muscle weakness.

It is especially important because it may occur as a paraneoplastic syndrome, classically in association with small-cell lung carcinoma.

1. Autoimmune Mechanism

In LEMS, autoantibodies are directed mainly against presynaptic P/Q-type voltage-gated calcium channels on the motor nerve terminal.

Normally, when a nerve impulse reaches the presynaptic terminal, voltage-gated calcium channels open and allow calcium to enter.

The calcium influx then triggers release of acetylcholine into the neuromuscular junction.

2. Effect of Calcium-Channel Antibodies

When these calcium channels are impaired by autoantibodies, less calcium enters the nerve terminal.

This causes reduced acetylcholine release.

The sequence is:

Antibodies against presynaptic Ca²⁺ channels → reduced Ca²⁺ entry → reduced acetylcholine release → impaired neuromuscular transmission → muscle weakness.

3. Paraneoplastic Association

LEMS has a particularly strong association with small-cell lung carcinoma (SCLC).

Small-cell carcinoma can express proteins resembling neuronal voltage-gated calcium channels.

The immune response directed against the tumour can therefore cross-react with calcium channels at the neuromuscular junction.

This produces a classic paraneoplastic neurological syndrome.

4. Non-Paraneoplastic LEMS

Not every patient with LEMS has cancer.

Some cases are purely autoimmune and may occur without an underlying malignancy.

However, because of the strong association with SCLC, patients with newly diagnosed LEMS generally require appropriate assessment for an underlying malignancy, particularly lung cancer.

5. Proximal Muscle Weakness

The characteristic weakness is predominantly proximal rather than distal.

The lower limbs are often affected first and most severely.

Patients may therefore complain of difficulty:

Rising from a chair.

Climbing stairs.

Getting out of bed.

Walking for prolonged periods.

Upper-limb proximal weakness may develop later.

6. Lower Limb Predominance

LEMS commonly affects the pelvic-girdle and thigh muscles before the upper limbs.

Patients may initially describe their legs as heavy or weak.

This lower-limb proximal pattern is an important clue when distinguishing LEMS from some other neuromuscular-junction disorders.

7. Facilitation with Exercise

A very characteristic feature of LEMS is that muscle strength may temporarily improve after brief exercise.

This is called facilitation or post-exercise improvement.

Repeated nerve activity allows calcium to accumulate within the presynaptic nerve terminal.

Even though calcium-channel function is reduced, the accumulated calcium allows more acetylcholine to be released.

Therefore:

Brief exercise → increased presynaptic Ca²⁺ accumulation → increased acetylcholine release → temporary improvement in strength.

8. Weakness with Sustained Activity

The original note states that weakness improves with exercise and then weakens again with sustained exercise.

This is a useful general concept.

The most characteristic finding is initial facilitation after brief activity. With prolonged or repeated exertion, the improvement may not persist, and fatigue can again become apparent.

Therefore, remember:

LEMS → brief exercise improves strength.

This contrasts with the classic fatigability of myasthenia gravis.

9. Reduced Reflexes

An important feature not included in the original notes is reduced or absent tendon reflexes.

Patients often have hyporeflexia or areflexia.

However, reflexes may temporarily improve after the patient contracts the relevant muscle for several seconds.

This phenomenon is another example of post-activation facilitation.

10. Autonomic Symptoms

LEMS frequently affects the autonomic nervous system because voltage-gated calcium channels also participate in autonomic neurotransmission.

Common autonomic symptoms include:

Dry mouth.

Constipation.

Erectile dysfunction.

Reduced sweating.

Orthostatic symptoms.

Dry mouth is particularly common.

11. Ocular and Bulbar Symptoms

Ocular symptoms such as ptosis and diplopia can occur, but they are usually less prominent than in myasthenia gravis.

Bulbar symptoms such as dysarthria or dysphagia may also occur but are generally less dominant.

This helps distinguish the typical clinical patterns of the two diseases.

12. LEMS versus Myasthenia Gravis

The two disorders both affect neuromuscular transmission but at different sites.

LEMS is presynaptic.

The autoantibodies attack voltage-gated calcium channels, reducing acetylcholine release.

Myasthenia gravis is mainly postsynaptic.

The immune system commonly attacks acetylcholine receptors or related postsynaptic proteins, impairing the muscle’s response to released acetylcholine.

13. Pattern of Weakness

In LEMS:

Proximal lower-limb weakness predominates.

Strength may initially improve with brief exercise.

Reflexes are often reduced.

Autonomic symptoms are common.

In myasthenia gravis:

Ocular and bulbar weakness are common.

Weakness generally worsens with repeated activity and improves with rest.

Reflexes are usually preserved.

Autonomic symptoms are not characteristic.

14. Electrophysiology

Nerve-conduction studies and repetitive nerve stimulation can support the diagnosis.

At rest, the compound muscle action potential may be reduced.

After brief exercise or high-frequency stimulation, there can be a marked increment in response amplitude.

This electrophysiological facilitation reflects increased acetylcholine release after repeated presynaptic stimulation.

15. Antibody Testing

Blood testing may detect antibodies against P/Q-type voltage-gated calcium channels.

A positive result supports the diagnosis when the clinical pattern is compatible.

However, diagnosis still depends on integrating symptoms, examination, electrophysiology, antibody results, and assessment for an underlying malignancy.

16. Investigation for Small-Cell Lung Cancer

Because LEMS may precede recognition of SCLC, patients should be evaluated for an underlying lung malignancy when clinically appropriate.

This may involve thoracic imaging and sometimes repeated surveillance if initial assessment is negative but clinical suspicion remains significant.

17. Treatment of the Underlying Tumour

When LEMS is associated with small-cell lung carcinoma, treating the malignancy is a crucial part of management.

Improvement in tumour control may also improve the neurological syndrome.

18. Amifampridine

A major symptomatic treatment for LEMS is amifampridine (3,4-diaminopyridine).

It blocks presynaptic potassium channels and prolongs depolarisation of the motor nerve terminal.

This allows more calcium to enter and increases acetylcholine release.

The sequence is:

K⁺ channel blockade → prolonged depolarisation → ↑ Ca²⁺ entry → ↑ acetylcholine release → improved muscle strength.

19. Other Treatment

Selected patients may require additional treatment such as pyridostigmine, although its benefit is usually less striking than in myasthenia gravis.

Immunomodulatory treatments may also be used in autoimmune disease, including corticosteroid-sparing therapy, intravenous immunoglobulin, or other specialist-directed therapy depending on severity.

20. Lambert–Eaton Syndrome – Note Form

Definition: autoimmune presynaptic neuromuscular-junction disorder.

Antibody target: P/Q-type voltage-gated calcium channels on the presynaptic motor nerve terminal.

Mechanism: reduced calcium entry → reduced acetylcholine release.

Classic malignancy: small-cell lung carcinoma.

Weakness: predominantly proximal.

Distribution: lower limbs usually affected more than upper limbs.

Exercise: strength characteristically improves temporarily after brief exercise.

Reflexes: reduced or absent but may improve after muscle activation.

Autonomic symptoms: dry mouth, constipation, erectile dysfunction, impaired sweating and orthostatic symptoms.

Ocular symptoms: can occur but are usually less prominent than in myasthenia gravis.

Electrophysiology: incremental response after exercise or high-frequency stimulation.

Treatment: treat underlying malignancy when present; amifampridine is an important symptomatic therapy.

Key Clinical Pattern

Remember LEMS as:

Proximal lower-limb weakness + reduced reflexes + autonomic symptoms + strength improves with brief exercise.

The mechanism is:

Presynaptic voltage-gated Ca²⁺ channel antibodies → ↓ acetylcholine release.

The classic association is:

Lambert–Eaton syndrome → small-cell lung carcinoma.

And the easiest comparison is:

LEMS → gets stronger initially with exercise + reflexes reduced + autonomic symptoms common.

Myasthenia gravis → gets weaker with repeated activity + reflexes preserved + ocular symptoms prominent.

Medicine – Multiple Sclerosis

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). It affects the brain, spinal cord, and optic nerves and is characterised by episodes of neurological dysfunction caused by inflammation, demyelination, and eventually varying degrees of axonal loss.

A central diagnostic concept is that lesions are disseminated in space and time—that is, they occur in different parts of the CNS and at different points in time.

1. Pathophysiology

MS is primarily an immune-mediated disease directed against components of CNS myelin and related neural tissue.

Both T-cell and B-cell immune mechanisms are involved.

Inflammatory cells cross the blood–brain barrier and contribute to:

Demyelination.

Oligodendrocyte injury.

Axonal damage.

Formation of plaques within CNS white matter and other regions.

Over time, repeated inflammatory injury can lead to irreversible neurodegeneration and disability.

2. Dissemination in Space and Time

The phrase “disseminated in time and place” is better expressed as:

Dissemination in space + dissemination in time.

Dissemination in space means lesions are found in different characteristic CNS locations.

Dissemination in time means there is evidence that lesions developed at different times.

This principle is central to modern MS diagnosis.

3. Typical Sites of Lesions

MS lesions commonly occur in areas such as:

Periventricular white matter.

Juxtacortical or cortical regions.

Infratentorial structures.

Spinal cord.

Optic nerves.

These locations help distinguish MS from many other white-matter disorders.

4. Clinical Presentation

MS can present in many different ways because lesions can occur throughout the CNS.

The percentages in older notes vary widely between studies, so they are best treated as historical approximations rather than fixed frequencies.

Common presenting symptoms include:

Weakness.

Optic neuritis.

Paraesthesiae or sensory disturbance.

Diplopia.

Bladder dysfunction.

Vertigo or imbalance.

5. Weakness

Patients may develop weakness affecting one or more limbs.

Because MS involves the CNS, weakness often has upper motor neurone features, such as:

Spasticity.

Hyperreflexia.

Extensor plantar responses.

Weakness may be focal, asymmetric, or involve both legs depending on lesion location.

6. Optic Neuritis

Optic neuritis is a classic presentation of MS.

Patients typically develop:

Subacute unilateral visual loss.

Pain on eye movement.

Reduced colour saturation, especially red.

Central scotoma.

Relative afferent pupillary defect.

The optic disc may appear normal initially if the inflammation is retrobulbar.

7. Sensory Symptoms

Paraesthesiae are common.

Patients may describe:

Pins and needles.

Numbness.

Burning sensations.

Tingling.

Electric-shock sensations.

A particularly characteristic symptom is Lhermitte phenomenon, in which flexion of the neck produces an electric-shock-like sensation down the spine or limbs due to cervical cord involvement.

8. Diplopia

Diplopia may occur because MS commonly affects brainstem pathways controlling eye movements.

One classic finding is internuclear ophthalmoplegia (INO) caused by involvement of the medial longitudinal fasciculus.

This produces impaired adduction of one eye with nystagmus of the abducting eye.

Bilateral INO in a young adult is strongly suggestive of MS.

9. Bladder Dysfunction

Bladder symptoms may occur due to spinal cord or supraspinal involvement.

Patients may develop:

Urgency.

Frequency.

Urge incontinence.

Difficulty emptying the bladder.

Retention in more advanced disease.

The original 5% figure should not be treated as universal because bladder dysfunction becomes common during the course of established MS.

10. Vertigo and Balance Problems

Brainstem and cerebellar lesions can cause:

Vertigo.

Ataxia.

Tremor.

Dysarthria.

Nystagmus.

Balance disturbance may significantly impair mobility even when limb strength is relatively preserved.

11. Other Important Symptoms

MS may also cause:

Fatigue.

Cognitive dysfunction.

Spasticity.

Neuropathic pain.

Sexual dysfunction.

Bowel dysfunction.

Mood disturbance.

Heat sensitivity.

Symptoms can fluctuate and may worsen temporarily with fever or increased body temperature.

12. Uhthoff Phenomenon

Uhthoff phenomenon refers to temporary worsening of previous neurological symptoms when body temperature rises.

This may occur with:

Exercise.

Hot weather.

Fever.

Hot baths.

It reflects impaired conduction through previously demyelinated nerve fibres rather than formation of a new lesion.

13. Relapsing-Remitting MS

The most common initial disease pattern is relapsing-remitting MS (RRMS).

Patients experience episodes of new or worsening neurological symptoms called relapses, followed by partial or complete recovery.

Relapses usually develop over hours to days and persist for at least 24 hours in the absence of fever or infection.

14. Secondary Progressive MS

Some patients with relapsing-remitting disease later develop secondary progressive MS (SPMS).

This is characterised by gradual worsening of neurological disability independent of clearly defined relapses.

Modern disease-modifying treatment aims partly to reduce the chance or delay the development of progressive disability.

15. Primary Progressive MS

A further important category is primary progressive MS (PPMS).

In this form, disability gradually worsens from the beginning without a typical initial relapsing-remitting pattern.

Patients often present with progressive spinal cord symptoms, particularly worsening gait and lower-limb stiffness.

16. MRI

MRI is the most important imaging investigation in suspected MS.

Typical lesions appear as areas of high signal intensity on T2-weighted and FLAIR sequences.

Characteristic distributions include:

Periventricular lesions.

Juxtacortical/cortical lesions.

Infratentorial lesions.

Spinal cord lesions.

17. Gadolinium Enhancement

Active inflammatory lesions may enhance after administration of gadolinium contrast.

The simultaneous presence of enhancing and non-enhancing lesions can provide evidence of lesions of different ages and therefore support dissemination in time.

Serial MRI can also demonstrate new lesions developing over time.

18. Dawson Fingers

A classic MRI feature is Dawson fingers.

These are ovoid periventricular lesions oriented roughly perpendicular to the lateral ventricles along medullary veins.

They are strongly associated with MS but are not completely specific.

19. Visual Evoked Potentials

Visual evoked potentials (VEPs) measure electrical responses in the visual pathway after a visual stimulus.

Demyelination slows nerve conduction and can produce delayed P100 latency.

This can provide evidence of previous optic pathway demyelination even when the patient has recovered clinically.

VEPs are less central to diagnosis than MRI but can still be useful in selected cases.

20. CSF Oligoclonal Bands

CSF examination may reveal oligoclonal IgG bands that are present in the CSF but absent from serum.

This indicates intrathecal immunoglobulin production.

Oligoclonal bands are found in many patients with MS and can support the diagnosis.

However, they are not specific to MS and may occur in other inflammatory or infectious CNS disorders.

21. CSF IgG Index

The IgG index may also be raised.

Routine CSF findings are otherwise often relatively mild:

Glucose usually normal.

Protein normal or mildly raised.

White cells normal or mildly lymphocytic.

Marked pleocytosis or very high protein should prompt consideration of another diagnosis.

22. Modern Diagnosis

Modern diagnosis generally uses the McDonald criteria, which combine:

Clinical attacks.

MRI evidence.

Dissemination in space.

Dissemination in time.

CSF oligoclonal bands in appropriate circumstances.

The diagnosis also requires exclusion of better alternative explanations.

23. Management Principles

MS management is ideally multidisciplinary.

Care may involve:

Neurology.

Physiotherapy.

Occupational therapy.

Specialist nursing.

Ophthalmology.

Urology.

Rehabilitation services.

Psychological and social support.

Management includes acute relapse treatment, disease-modifying therapy, symptom control, and rehabilitation.

24. Acute Relapse Treatment

Significant acute relapses are commonly treated with high-dose corticosteroids.

A traditional regimen is intravenous methylprednisolone for 3–5 days, although high-dose oral regimens may also be used in appropriate settings.

Steroids accelerate recovery from the relapse but do not necessarily improve the ultimate long-term neurological outcome from that particular attack.

25. Disease-Modifying Therapy

Modern MS treatment includes a wide range of disease-modifying therapies (DMTs) designed to reduce relapse frequency, MRI activity, and disability accumulation.

These include injectable, oral, and monoclonal-antibody treatments.

Choice depends on disease activity, patient factors, pregnancy considerations, adverse-effect profile, monitoring requirements, and local guidelines.

26. Interferon-β

Interferon-beta was one of the earliest widely used disease-modifying therapies.

It can reduce:

Relapse frequency.

MRI inflammatory activity.

Disease activity in relapsing forms of MS.

However, it is no longer the only or necessarily preferred treatment because many newer DMTs are available.

27. Interferon-β and Secondary Progressive MS

The older statement that interferon-beta is routinely used in secondary progressive MS needs qualification.

Its benefit is mainly in relapsing disease with ongoing inflammatory activity.

In secondary progressive MS without active relapses or MRI inflammatory activity, interferon-beta is generally much less useful.

Modern treatment for active progressive disease may involve other disease-modifying agents depending on the exact phenotype and local approval.

28. Symptomatic Treatment

Symptom management is an important part of long-term care.

Examples include treatment for:

Spasticity.

Neuropathic pain.

Bladder dysfunction.

Fatigue.

Depression.

Mobility impairment.

Sexual dysfunction.

Physiotherapy and rehabilitation are often as important as medication for maintaining function and independence.

29. Multiple Sclerosis – Note Form

Definition: chronic immune-mediated inflammatory demyelinating disease of the CNS.

Pathology: inflammation + demyelination + axonal loss.

Diagnostic principle: lesions disseminated in space and time.

Common sites: periventricular, juxtacortical/cortical, infratentorial, spinal cord and optic nerve.

Weakness: often upper motor neurone type with spasticity and hyperreflexia.

Optic neuritis: painful subacute unilateral visual loss with red desaturation.

Sensory symptoms: paraesthesiae, numbness and Lhermitte phenomenon.

Diplopia: may result from internuclear ophthalmoplegia.

Bladder dysfunction: urgency, frequency, retention or incontinence may occur.

Vertigo/ataxia: due to brainstem or cerebellar lesions.

MRI: T2/FLAIR hyperintense white-matter lesions in characteristic locations.

Active lesions: may enhance with gadolinium.

VEP: delayed visual evoked response due to slowed conduction.

CSF: oligoclonal IgG bands present in CSF but not serum; not completely specific.

Acute relapse: high-dose corticosteroids such as methylprednisolone.

Long-term treatment: disease-modifying therapy selected according to disease type and activity.

Interferon-β: reduces relapses in relapsing forms of MS but is only one of many modern DMT options.

Key Clinical Pattern

Remember MS as:

Young adult + neurological episodes separated in time + lesions in different CNS locations.

The most useful clues are:

Optic neuritis.

Sensory disturbance.

Upper motor neurone weakness.

Internuclear ophthalmoplegia.

Ataxia.

Bladder dysfunction.

And the key investigations are:

MRI → characteristic T2/FLAIR lesions.

CSF → oligoclonal bands.

VEP → delayed conduction.

The core diagnostic concept is:

Multiple sclerosis = dissemination in space + dissemination in time.

Medicine – CSF Protein

CSF protein concentration rises when there is disruption of the blood–CSF barrier, inflammation, infection, impaired CSF circulation, tumour, or damage to nerve roots. The degree of elevation can therefore help narrow the differential diagnosis, although it is never interpreted in isolation.

Normal CSF protein is relatively low, typically around 0.15–0.45 g/L in adults, depending on the laboratory and age.

1. Markedly Raised CSF Protein

A markedly raised CSF protein, for example in the range of about 2–6 g/L, suggests a limited group of important disorders.

These include:

Guillain–Barré syndrome.

Spinal block, including tumour-related obstruction.

Tuberculous meningitis.

Fungal meningitis.

2. Guillain–Barré Syndrome

Guillain–Barré syndrome (GBS) classically produces:

High CSF protein + normal or only mildly raised white-cell count.

This is called albuminocytologic dissociation.

The protein rises because inflammation and demyelination of spinal nerve roots increase protein leakage into the CSF, while there is usually no large pleocytosis.

A useful examination pattern is:

Progressive ascending weakness + areflexia + high CSF protein with few cells = GBS.

3. Timing in Guillain–Barré Syndrome

An important point is that CSF protein may be normal early in GBS, particularly during the first few days.

It often rises after about the first week.

Therefore, a normal early CSF protein does not completely exclude GBS.

4. Spinal Block

A spinal block caused by a tumour or other obstructing lesion can produce a very high CSF protein.

The obstruction interferes with normal CSF circulation, allowing protein to accumulate below the level of the block.

This can sometimes produce a strikingly high protein concentration.

5. Froin Syndrome

Severe spinal CSF obstruction can produce Froin syndrome.

This is characterised by:

Very high CSF protein + xanthochromia + spontaneous clotting of CSF.

It occurs because stagnant CSF below a spinal block becomes concentrated with protein.

6. Tuberculous Meningitis

TB meningitis frequently causes a substantial rise in CSF protein.

The classic CSF pattern is:

Lymphocytes ↑ + protein ↑↑↑ + glucose ↓↓ + opening pressure ↑.

Protein may become very high because chronic meningeal inflammation disrupts the blood–CSF barrier.

7. Fungal Meningitis

Fungal meningitis, including cryptococcal meningitis, can also produce markedly elevated CSF protein.

The pattern often resembles TB meningitis:

Lymphocytes/mononuclear cells ↑ + protein ↑↑ + glucose ↓.

Opening pressure may also be raised, especially in cryptococcal disease.

8. Moderately Raised CSF Protein

A less extreme rise in CSF protein can occur in many neurological disorders.

Important causes include:

Bacterial meningitis.

Viral encephalitis or meningitis.

Cerebral abscess.

Multiple sclerosis.

Primary or metastatic cerebral tumours.

9. Bacterial Meningitis

In acute bacterial meningitis, CSF protein is commonly markedly elevated, often more than in viral disease.

The typical pattern is:

Neutrophils ↑↑ + glucose ↓↓ + protein ↑↑.

The protein rises because severe meningeal inflammation increases permeability of the blood–CSF barrier.

10. Viral Encephalitis

Viral encephalitis generally causes a mild to moderate rise in CSF protein.

The typical CSF pattern is:

Lymphocytes ↑ + protein ↑ + glucose usually normal.

HSV encephalitis may also produce red cells in the CSF because of haemorrhagic temporal-lobe necrosis.

11. Cerebral Abscess

A brain abscess may cause a moderate rise in CSF protein due to nearby inflammation or disruption of the blood–CSF barrier.

However, lumbar puncture is often not the key diagnostic test for suspected brain abscess and may be unsafe if there is raised intracranial pressure or mass effect.

Neuroimaging is usually more important.

12. Multiple Sclerosis

In multiple sclerosis, total CSF protein may be normal or mildly elevated.

A large protein rise is unusual and should prompt consideration of another diagnosis.

The more characteristic CSF findings in MS are:

CSF-restricted oligoclonal IgG bands.

Raised IgG index.

Mild lymphocytic pleocytosis in some cases.

13. Cerebral Tumours

Both primary brain tumours and cerebral metastases can raise CSF protein.

This may occur because of:

Disruption of the blood–CSF barrier.

Tumour involvement of the meninges.

Obstruction of CSF flow.

The degree of elevation varies widely.

14. Leptomeningeal Malignancy

When malignant cells spread to the meninges, CSF protein can be substantially raised.

Other findings may include:

Low CSF glucose.

Raised opening pressure.

Malignant cells on cytology.

Therefore, a high protein together with low glucose and abnormal cells should raise suspicion for leptomeningeal malignancy.

15. CSF Protein – Note Form

Markedly raised protein, around 2–6 g/L:

Guillain–Barré syndrome.

Spinal block.

TB meningitis.

Fungal meningitis.

Raised protein:

Bacterial meningitis.

Viral encephalitis/meningitis.

Cerebral abscess.

Multiple sclerosis, usually only mildly.

Primary or metastatic cerebral tumours.

16. High-Yield Patterns

GBS → high protein + few cells.

This is albuminocytologic dissociation.

TB meningitis → high protein + lymphocytes + low glucose.

Fungal meningitis → high protein + lymphocytes + low glucose.

Bacterial meningitis → high protein + neutrophils + low glucose.

Viral meningitis/encephalitis → moderately high protein + lymphocytes + normal glucose.

MS → protein normal or mildly raised + oligoclonal bands.

Key Clinical Pattern

The most useful way to remember CSF protein is:

Very high protein with few cells → GBS or spinal block.

Very high protein with lymphocytes and low glucose → TB or fungal meningitis.

High protein with neutrophils and low glucose → bacterial meningitis.

Mild/moderate protein rise with lymphocytes and normal glucose → viral infection.

Mild protein rise + oligoclonal bands → multiple sclerosis.

Medicine – Cells in Cerebrospinal Fluid (CSF)

The type of white blood cell present in cerebrospinal fluid provides an important clue to the underlying neurological disorder. The most useful distinction is between neutrophilic (polymorph) predominance and lymphocytic predominance.

However, cell patterns are not completely specific and can change with the stage of illness, prior antibiotic treatment, and underlying immune status.

1. Polymorphs in CSF

Polymorphs, meaning mainly neutrophils, are classically associated with acute bacterial meningitis.

The usual pattern is:

Neutrophils ↑↑ + protein ↑↑ + glucose ↓↓.

Bacterial Meningitis

In acute bacterial meningitis, the meninges become intensely inflamed and large numbers of neutrophils migrate into the CSF.

The cell count may rise into the hundreds or thousands per microlitre.

Common associated findings include:

Raised opening pressure.

Turbid CSF.

Low CSF glucose.

Markedly raised protein.

Important Exception

Neutrophils are not exclusive to bacterial meningitis.

Early viral meningitis, particularly during the first hours of illness, may sometimes show a temporary neutrophilic predominance before becoming lymphocyte-predominant.

Therefore, the full CSF pattern and clinical context must be considered.

2. Lymphocytes in CSF

A lymphocytic or mononuclear predominance is classically associated with viral, chronic infectious, inflammatory, malignant, or immune-mediated CNS disorders.

The major causes from your notes include:

Viral meningitis or encephalitis.

Partially treated bacterial meningitis.

CNS vasculitis.

HIV-associated neurological disease.

Leukaemia.

3. Viral Meningitis

Typical viral meningitis produces a lymphocytic pleocytosis.

The usual pattern is:

Lymphocytes ↑ + protein mildly/moderately ↑ + glucose usually normal.

Patients often present with headache, fever, photophobia, neck stiffness, and relatively preserved consciousness compared with severe bacterial meningitis.

4. Viral Encephalitis

Viral encephalitis also usually produces a lymphocyte-predominant CSF response.

However, because encephalitis involves the brain parenchyma rather than only the meninges, patients are more likely to have:

Altered consciousness.

Confusion or behavioural change.

Seizures.

Focal neurological deficits.

HSV Encephalitis

Herpes simplex virus encephalitis is an especially important cause.

CSF typically shows:

Lymphocytic pleocytosis.

Raised protein.

Usually normal glucose.

Red blood cells may sometimes be present because HSV encephalitis can cause haemorrhagic necrosis, particularly in the temporal lobes.

Diagnosis is usually supported by CSF HSV PCR.

5. Partially Treated Bacterial Meningitis

Bacterial meningitis that has already received antibiotics may show an altered CSF pattern.

The cell differential can become less typically neutrophilic and may become relatively lymphocyte-predominant.

Therefore:

Lymphocytes in CSF do not completely exclude bacterial meningitis, especially after prior antibiotic therapy.

Other findings such as low glucose and high protein may still support bacterial infection.

6. Tuberculous Meningitis

Although not listed in your current note, TB meningitis is one of the most important causes of lymphocytic CSF.

The classic pattern is:

Lymphocytes ↑ + protein ↑↑↑ + glucose ↓↓ + opening pressure ↑.

This is a high-yield distinction from uncomplicated viral meningitis.

7. Fungal Meningitis

Chronic fungal meningitis, including cryptococcal meningitis, also commonly causes a mononuclear or lymphocytic CSF pattern.

The typical combination is:

Lymphocytes/mononuclear cells ↑ + protein ↑ + glucose ↓.

This can closely resemble TB meningitis.

8. CNS Vasculitis

Central nervous system vasculitis may cause a mild inflammatory CSF picture.

CSF may show:

Lymphocytic pleocytosis.

Raised protein.

Glucose is usually relatively preserved.

These findings are nonspecific, so diagnosis depends on the broader clinical picture, imaging, laboratory tests, and occasionally vascular imaging or biopsy.

9. HIV-Associated Disease

Patients with HIV infection can develop a variety of CNS disorders associated with lymphocytes in the CSF.

This may occur with HIV itself or with opportunistic infections.

Examples include:

HIV-associated aseptic meningitis.

Cryptococcal meningitis.

Tuberculous meningitis.

Viral CNS infections.

Therefore, in an immunocompromised patient, CSF findings must be interpreted cautiously because inflammatory cell responses may sometimes be relatively modest despite severe infection.

10. Leukaemia

Leukaemia can involve the meninges and central nervous system.

Malignant cells may enter the CSF, producing leptomeningeal leukaemic involvement.

The CSF may contain increased mononuclear cells, but the key diagnostic issue is identifying abnormal malignant cells, rather than simply calling the response lymphocytic.

11. CSF Cytology

When malignant CNS involvement is suspected, CSF cytology is important.

Flow cytometry can also be especially valuable for detecting haematological malignancy involving the CSF.

In some cases, repeated lumbar punctures may be needed because malignant cells may not be detected in the first sample.

12. Other Causes of Lymphocytic CSF

Other important causes include:

Multiple sclerosis, which may produce a mild lymphocytic pleocytosis.

Neurosarcoidosis.

Syphilitic meningitis.

Lyme neuroborreliosis.

Autoimmune encephalitis.

These conditions generally produce much lower cell counts than acute bacterial meningitis.

13. Polymorphs – Note Form

Main association: acute bacterial meningitis.

Typical accompanying findings: low glucose + very high protein + raised opening pressure.

Important exception: early viral meningitis can temporarily show neutrophils.

14. Lymphocytes – Note Form

Viral meningitis: lymphocytes + normal glucose + moderately raised protein.

Viral encephalitis: lymphocytes + raised protein, usually normal glucose.

Partially treated bacterial meningitis: may become lymphocyte-predominant.

TB meningitis: lymphocytes + low glucose + very high protein.

Fungal meningitis: lymphocytes/mononuclear cells + low glucose + high protein.

CNS vasculitis: mild lymphocytic pleocytosis + raised protein.

HIV-associated CNS disease: often mononuclear/lymphocytic, but pattern depends on the underlying infection or process.

Leukaemia: malignant mononuclear cells may be present; confirm with cytology/flow cytometry.

Key Clinical Pattern

Remember:

Polymorphs/neutrophils → think bacterial meningitis.

Lymphocytes → think viral, TB, fungal, inflammatory, or malignant disease.

The fastest examination distinction is:

Neutrophils + low glucose → bacterial meningitis.

Lymphocytes + normal glucose → viral meningitis.

Lymphocytes + low glucose → TB or fungal meningitis.

Abnormal malignant cells → leukaemia or leptomeningeal malignancy.

Infectious Disease and Microbiology – Gemella Species

Overview

Gemella species are Gram-positive cocci that are part of the normal human mucosal flora but occasionally cause invasive disease. Human infections are rare, with infective endocarditis and bacteremia representing the most important clinical manifestations.

An important microbiologic feature is that Gemella can be misidentified as viridans group streptococci, particularly with conventional laboratory methods.

Important Species

Clinically important species include:

• Gemella haemolysans

• Gemella morbillorum

Both have been associated with invasive infections, particularly endocarditis.

Microbiologic Characteristics

Gemella species are:

• Gram-positive cocci

• Facultatively anaerobic

• Catalase-negative

• Often arranged in pairs, short chains, or clusters

• Occasionally Gram-variable on staining

Because of their appearance and biochemical characteristics, isolates may be confused with viridans streptococci.

Normal Flora

Gemella species may colonize normal human mucosal surfaces, particularly the:

• Oral cavity

• Upper respiratory tract

• Gastrointestinal tract

Therefore, invasive infection may develop when organisms gain access to the bloodstream through disrupted mucosal surfaces.

Epidemiology

Gemella species have a worldwide distribution, but clinically significant infections are uncommon.

Most reported disease represents opportunistic or endogenous infection arising from the patient’s own colonizing flora.

Endocarditis

The most important invasive infection caused by Gemella is:

Infective endocarditis

Endocarditis may occur after transient or sustained bacteremia, potentially originating from the oral cavity or gastrointestinal tract.

Clinical manifestations may include:

• Fever

• Malaise

• New or changing cardiac murmur

• Persistent bacteremia

• Embolic phenomena

Association With Oral Disease

Because Gemella can inhabit the oral cavity, some cases of endocarditis have been associated with:

• Poor dentition

• Dental infection

• Recent dental procedures

• Other disruption of oral mucosal integrity

This clinical pattern can resemble endocarditis caused by viridans streptococci.

Bacteremia

Gemella species can cause bacteremia, either as an isolated bloodstream infection or in association with a deeper infectious focus such as endocarditis.

Persistent positive blood cultures should prompt investigation for an underlying source.

Pneumonia

Rare cases of pneumonia associated with Gemella species have been reported.

Because the organism may colonize the upper respiratory tract, isolation from respiratory material must be interpreted within the clinical context.

Urinary Tract Infection

Gemella species have occasionally been recovered from patients with urinary tract infections, although this is an uncommon manifestation.

Wound Infection and Abscesses

Rare infections include:

• Wound infection

• Soft-tissue infection

• Abscess formation

As with other organisms originating from normal flora, disruption of tissue barriers may facilitate invasive disease.

Prosthetic Joint Infection

Gemella species have rarely caused infections involving total knee arthroplasties and other prosthetic joints.

Prosthetic-device infection may require:

Antimicrobial therapy

• ●

Appropriate surgical/source control

depending on the clinical circumstances.

Arteriovenous Shunt Infection

Rare cases involving arteriovenous shunts have also been described.

This demonstrates the ability of Gemella species to cause infections involving implanted or intravascular medical material.

Diagnosis

Diagnosis is established primarily by:

Culture

Blood cultures are particularly important when bacteremia or endocarditis is suspected.

Laboratory Identification

A major diagnostic issue is potential confusion between:

Gemella species

and

Viridans group streptococci

Modern identification methods can improve species-level recognition when conventional biochemical testing is inconclusive.

Diagnosis of Endocarditis

When Gemella is repeatedly isolated from blood cultures, particularly in a patient with compatible symptoms, evaluation for infective endocarditis should be considered.

This generally involves:

Repeated blood cultures

• ●

Echocardiographic evaluation

• ●

Assessment for embolic or other complications

Treatment

The source lists:

Penicillin G

as the primary treatment.

Many Gemella isolates have historically demonstrated susceptibility to β-lactam antibiotics, although susceptibility testing is useful in significant invasive disease.

Additional Treatment

Alternative agents listed in the source include:

• Vancomycin

• Macrolides

For serious infections such as endocarditis, antimicrobial therapy should be selected according to susceptibility results and the clinical syndrome.

High-Yield Clinical Pattern

Gram-positive coccus

• ●

May be mistaken for viridans streptococci

• ●

Bacteremia

• ●

Infective endocarditis

→ Think Gemella species

Endocarditis Pattern

Oral flora organism

• ●

Possible dental/oral source

• ●

Persistent bacteremia

• ●

Cardiac valve vegetation

→ Consider Gemella endocarditis

Gemella vs. Viridans Streptococci

Gemella:

Gram-positive/occasionally Gram-variable cocci + rare invasive pathogen + important association with endocarditis

Viridans streptococci:

Gram-positive cocci + common oral flora + classic cause of subacute endocarditis

The two may appear similar with conventional microbiologic testing.

Exam Essentials

Genus: Gemella

Important species: G. haemolysans, G. morbillorum

Morphology: Gram-positive cocci

Distribution: Worldwide

Frequency of infection: Rare

Normal habitat: Primarily oral and other mucosal flora

Important diagnostic confusion: Viridans streptococci

Major infection: Endocarditis

Other major manifestation: Bacteremia

Rare infections: Pneumonia, UTI, wound infection, abscesses

Device infections: Prosthetic joint and arteriovenous shunt infection

Diagnosis: Culture

Treatment in source: Penicillin G

Additional agents: Vancomycin, macrolides

Management principle: Susceptibility-guided treatment for serious invasive disease

Key clinical pearl: Gemella is a rare Gram-positive coccus that can resemble viridans streptococci in the laboratory. Its most important invasive association is infective endocarditis, often fitting the clinical pattern of an oral-flora organism producing bacteremia and valvular infection.

Infectious Disease and Microbiology – Gardnerella vaginalis

Overview

Gardnerella vaginalis is a small, pleomorphic bacterium strongly associated with bacterial vaginosis (BV). BV results from disruption of the normal vaginal microbiota, with loss of protective Lactobacillus predominance and overgrowth of Gardnerella together with other anaerobic organisms.

Although primarily associated with bacterial vaginosis, G. vaginalis can occasionally cause postpartum endometritis, urinary tract infection, and bacteremia.

Microbiologic Characteristics

Gardnerella vaginalis is:

• A small pleomorphic bacillus/coccobacillus

• Facultatively anaerobic

• Gram-variable, rather than reliably Gram-negative

• Associated with polymicrobial vaginal biofilms

The source describes it as an aerobic Gram-negative bacillus, but Gram-variable coccobacillus/facultative anaerobe is a more accurate microbiologic description.

Epidemiology

G. vaginalis occurs worldwide.

Importantly, Gardnerella may be present in the vaginal microbiota without producing symptoms. Therefore, simply detecting the organism does not by itself establish bacterial vaginosis.

BV reflects a broader vaginal microbial dysbiosis rather than infection by G. vaginalis alone.

Bacterial Vaginosis

The most important clinical association is:

Gardnerella vaginalis → bacterial vaginosis

In BV, normal hydrogen-peroxide/lactic-acid-producing lactobacilli decrease and are replaced by increased concentrations of Gardnerella and multiple anaerobic organisms.

Clinical Features of Bacterial Vaginosis

Typical manifestations include:

• Thin, homogeneous vaginal discharge

• White or gray discharge

• Characteristic fishy odor

• Minimal vaginal inflammation in many patients

Pruritus and marked inflammatory changes are less characteristic than in vulvovaginal candidiasis or trichomoniasis.

Clue Cells

A classic microscopic finding is the:

Clue cell

Clue cells are vaginal epithelial cells whose surfaces are densely coated with bacteria, producing indistinct or stippled cellular borders.

They are strongly associated with bacterial vaginosis.

Amsel Criteria

A classic clinical diagnosis of bacterial vaginosis can be made using the Amsel criteria.

The findings are:

• Thin, homogeneous vaginal discharge

• Vaginal pH >4.5

• Positive amine (“whiff”) test after adding potassium hydroxide

• Clue cells on microscopy

The presence of at least 3 of the 4 criteria supports the diagnosis of bacterial vaginosis.

Fishy Odor

The characteristic odor results from volatile amines produced by the altered vaginal microbial community.

The odor may become more apparent after adding potassium hydroxide during the whiff test.

Postpartum Endometritis

G. vaginalis has also been implicated in postpartum endometritis.

These infections are frequently polymicrobial and may involve organisms originating from the lower genital tract.

Urinary Tract Infection

Urinary infection associated with G. vaginalis has been reported, including in pregnant women.

Because the organism may colonize the genital tract, its recovery from urinary specimens should be interpreted together with symptoms and specimen quality.

Bacteremia

Although uncommon, G. vaginalis can cause bacteremia and other invasive infections.

Systemic infection is much less common than bacterial vaginosis.

Diagnosis

The source describes:

• Culture using specific media

• Identification of clue cells on vaginal smears

For bacterial vaginosis, however, routine culture of G. vaginalis is generally not the preferred diagnostic strategy because the organism can also occur in people without BV.

Gram Stain

A vaginal Gram stain can be assessed using the Nugent scoring system, which evaluates changes in vaginal bacterial morphotypes.

A pattern showing decreased lactobacilli with increased organisms characteristic of BV supports the diagnosis.

Treatment of Bacterial Vaginosis

The source emphasizes:

Metronidazole

as highly effective for bacterial vaginosis.

Metronidazole works well clinically because BV is a polymicrobial syndrome involving anaerobic organisms, even though susceptibility testing of G. vaginalis alone may not fully predict clinical response.

Topical Treatment

The source also describes local treatment with:

• Metronidazole

• Clindamycin

These can be administered as vaginal preparations for bacterial vaginosis.

Additional Treatment

Additional antimicrobial options described in the source include:

• Amoxicillin–clavulanate

• Clindamycin

For systemic or urinary infections, the source recommends:

• Ampicillin

• Amoxicillin

Treatment of invasive infection should be individualized according to the clinical syndrome and antimicrobial susceptibility information.

Important Clinical Distinction

Bacterial vaginosis is generally characterized by:

Altered vaginal flora + discharge + fishy odor

rather than prominent inflammation.

Therefore:

BV → vaginosis rather than classic inflammatory vaginitis

This helps distinguish it from conditions such as candidiasis and trichomoniasis.

High-Yield Clinical Pattern

Thin, homogeneous gray-white vaginal discharge

• ●

Fishy odor

• ●

Vaginal pH >4.5

• ●

Clue cells

→ Think bacterial vaginosis associated with Gardnerella vaginalis

Exam Essentials

Organism: Gardnerella vaginalis

Morphology: Small pleomorphic Gram-variable coccobacillus

Metabolism: Facultatively anaerobic

Distribution: Worldwide

Major association: Bacterial vaginosis

Pathogenesis: Loss of Lactobacillus predominance + polymicrobial overgrowth/biofilm

Discharge: Thin, homogeneous, gray-white

Characteristic odor: Fishy

Vaginal pH: >4.5

Microscopy: Clue cells

Whiff test: Positive

Clinical diagnostic method: Amsel criteria

Gram-stain method: Nugent score

Other infections: Postpartum endometritis, UTI, bacteremia

Main treatment in source: Metronidazole

Alternative BV treatment: Clindamycin

Culture: Not generally required to diagnose routine BV

Bacterial Vaginosis vs. Candidiasis

Bacterial vaginosis:

Thin gray-white discharge + fishy odor + pH >4.5 + clue cells

Vulvovaginal candidiasis:

Thick white discharge + prominent pruritus/inflammation + usually normal vaginal pH + yeast/pseudohyphae

Key clinical pearl: Gardnerella vaginalis is strongly associated with bacterial vaginosis, but BV is a polymicrobial dysbiosis rather than a simple single-organism infection. The classic examination combination is thin gray-white discharge, fishy odor, vaginal pH >4.5, and clue cells.

Microbiologic Characteristics Gardnerella vaginalis is: • A small pleomorphic bacillus/coccobacillus

• Facultatively anaerobic

• Gram-variable, rather than reliably Gram-negative

• Associated with polymicrobial vaginal biofilms The source describes it as an aerobic Gram-negative bacillus, but Gram-variable coccobacillus/facultative anaerobe is a more accurate microbiologic description.

Epidemiology G. vaginalis occurs worldwide. Importantly, Gardnerella may be present in the vaginal microbiota without producing symptoms. Therefore, simply detecting the organism does not by itself establish bacterial vaginosis. BV reflects a broader vaginal microbial dysbiosis rather than infection by G. vaginalis alone.

Bacterial Vaginosis The most important clinical association is: Gardnerella vaginalis → bacterial vaginosis In BV, normal hydrogen-peroxide/lactic-acid-producing lactobacilli decrease and are replaced by increased concentrations of Gardnerella and multiple anaerobic organisms.

Clinical Features of Bacterial Vaginosis Typical manifestations include: • Thin, homogeneous vaginal discharge

• White or gray discharge

• Characteristic fishy odor

• Minimal vaginal inflammation in many patients Pruritus and marked inflammatory changes are less characteristic than in vulvovaginal candidiasis or trichomoniasis.

Clue Cells A classic microscopic finding is the: Clue cell Clue cells are vaginal epithelial cells whose surfaces are densely coated with bacteria, producing indistinct or stippled cellular borders. They are strongly associated with bacterial vaginosis.

Amsel Criteria A classic clinical diagnosis of bacterial vaginosis can be made using the Amsel criteria. The findings are: • Thin, homogeneous vaginal discharge

• Vaginal pH >4.5

• Positive amine (“whiff”) test after adding potassium hydroxide

• Clue cells on microscopy The presence of at least 3 of the 4 criteria supports the diagnosis of bacterial vaginosis.

Fishy Odor The characteristic odor results from volatile amines produced by the altered vaginal microbial community. The odor may become more apparent after adding potassium hydroxide during the whiff test.

Postpartum Endometritis G. vaginalis has also been implicated in postpartum endometritis. These infections are frequently polymicrobial and may involve organisms originating from the lower genital tract.

Urinary Tract Infection Urinary infection associated with G. vaginalis has been reported, including in pregnant women. Because the organism may colonize the genital tract, its recovery from urinary specimens should be interpreted together with symptoms and specimen quality.

Bacteremia Although uncommon, G. vaginalis can cause bacteremia and other invasive infections. Systemic infection is much less common than bacterial vaginosis.

Diagnosis The source describes: • Culture using specific media

• Identification of clue cells on vaginal smears For bacterial vaginosis, however, routine culture of G. vaginalis is generally not the preferred diagnostic strategy because the organism can also occur in people without BV.

Gram Stain A vaginal Gram stain can be assessed using the Nugent scoring system, which evaluates changes in vaginal bacterial morphotypes. A pattern showing decreased lactobacilli with increased organisms characteristic of BV supports the diagnosis.

Treatment of Bacterial Vaginosis The source emphasizes: Metronidazole as highly effective for bacterial vaginosis. Metronidazole works well clinically because BV is a polymicrobial syndrome involving anaerobic organisms, even though susceptibility testing of G. vaginalis alone may not fully predict clinical response.

Topical Treatment The source also describes local treatment with: • Metronidazole

• Clindamycin These can be administered as vaginal preparations for bacterial vaginosis.

Additional Treatment Additional antimicrobial options described in the source include: • Amoxicillin–clavulanate

• Clindamycin For systemic or urinary infections, the source recommends: • Ampicillin

• Amoxicillin Treatment of invasive infection should be individualized according to the clinical syndrome and antimicrobial susceptibility information.

Important Clinical Distinction Bacterial vaginosis is generally characterized by: Altered vaginal flora + discharge + fishy odor rather than prominent inflammation. Therefore: BV → vaginosis rather than classic inflammatory vaginitis This helps distinguish it from conditions such as candidiasis and trichomoniasis.

High-Yield Clinical Pattern Thin, homogeneous gray-white vaginal discharge  ●  Fishy odor  ●  Vaginal pH >4.5  ●  Clue cells → Think bacterial vaginosis associated with Gardnerella vaginalis

Exam Essentials Organism: Gardnerella vaginalis

Morphology: Small pleomorphic Gram-variable coccobacillus

Metabolism: Facultatively anaerobic

Distribution: Worldwide

Major association: Bacterial vaginosis

Pathogenesis: Loss of Lactobacillus predominance + polymicrobial overgrowth/biofilm

Discharge: Thin, homogeneous, gray-white

Characteristic odor: Fishy

Vaginal pH: >4.5

Microscopy: Clue cells

Whiff test: Positive

Clinical diagnostic method: Amsel criteria

Gram-stain method: Nugent score

Other infections: Postpartum endometritis, UTI, bacteremia

Main treatment in source: Metronidazole

Alternative BV treatment: Clindamycin

Culture: Not generally required to diagnose routine BV

Bacterial Vaginosis vs. Candidiasis Bacterial vaginosis:

Thin gray-white discharge + fishy odor + pH >4.5 + clue cells Vulvovaginal candidiasis:

Thick white discharge + prominent pruritus/inflammation + usually normal vaginal pH + yeast/pseudohyphae

Key clinical pearl: Gardnerella vaginalis is strongly associated with bacterial vaginosis, but BV is a polymicrobial dysbiosis rather than a simple single-organism infection. The classic examination combination is thin gray-white discharge, fishy odor, vaginal pH >4.5, and clue cells.

Infectious Disease and Microbiology – Fusobacterium Species

Overview

Fusobacterium species are anaerobic Gram-negative bacilli that normally colonize the oral cavity and gastrointestinal tract. Most infections are endogenous, developing when organisms from the patient’s normal flora invade normally sterile tissues.

They commonly participate in polymicrobial abscesses and necrotizing infections. A particularly important species is Fusobacterium necrophorum, which is classically associated with Lemierre syndrome—postpharyngitis sepsis with internal jugular vein septic thrombophlebitis and metastatic infection.

⸻

Important Species

Species traditionally included in this group include:

• Fusobacterium alocis

• Fusobacterium mortiferum

• Fusobacterium necrophorum

• Fusobacterium nucleatum

• Fusobacterium periodonticum

• Fusobacterium sulci

• Fusobacterium ulcerans

• Fusobacterium varium

• Other Fusobacterium species

F. necrophorum and F. nucleatum are particularly important in human infectious disease.

⸻

Microbiologic Characteristics

Fusobacterium species are:

• Gram-negative bacilli

• Obligate anaerobes

• Common members of normal oral and gastrointestinal flora

• Important causes of endogenous anaerobic infection

The organisms are often described morphologically as slender or fusiform Gram-negative rods.

⸻

Incubation and Source of Infection

A conventional incubation period is generally not applicable because most infections originate from the patient’s own microbial flora.

The typical sequence is:

Normal oral or bowel colonization

→

Mucosal disruption or local infection

→

Invasion of deeper tissue

→

Abscess, bacteremia, or metastatic infection

⸻

Epidemiology

Fusobacterium species commonly colonize the:

• Oral cavity

• Oropharynx

• Gastrointestinal tract

Their presence as normal flora means that infection commonly develops when anatomic barriers are disrupted.

⸻

Clinical Infections

Fusobacterium species can cause:

• Cervicofacial infections

• Pleuropulmonary infections

• Intra-abdominal infections

• Pelvic infections

• Soft-tissue infections

• Surgical wound infections

• Bite-wound infections

• Bacteremia and sepsis

• Endocarditis

Abscesses are common and are frequently polymicrobial.

⸻

Cervicofacial Infection

Because Fusobacterium commonly inhabits the oral cavity, it can participate in cervicofacial and odontogenic infections.

These infections may include:

• Dental and periodontal infection

• Deep neck-space infection

• Peritonsillar infection

• Cervicofacial abscess formation

⸻

Pleuropulmonary Infection

Aspiration of oral secretions containing anaerobic organisms may result in:

• Aspiration pneumonia

• Lung abscess

• Necrotizing pulmonary infection

• Empyema

These infections are frequently polymicrobial and may include other anaerobic components of the oral flora.

⸻

Intra-Abdominal and Pelvic Infection

Because fusobacteria can form part of gastrointestinal flora, they may participate in:

• Intra-abdominal abscesses

• Peritonitis

• Pelvic abscesses

• Other polymicrobial abdominal infections

Source control is often important when an abscess is present.

⸻

Soft-Tissue and Wound Infection

Fusobacterium species can cause soft-tissue and wound infections, including infections following:

• Surgery

• Human or animal bites

• Tissue trauma

These infections commonly involve multiple aerobic and anaerobic organisms.

⸻

Lemierre Syndrome

The most important high-yield association is:

Fusobacterium necrophorum → Lemierre syndrome

This condition classically develops in an otherwise healthy adolescent or young adult following pharyngitis or tonsillitis.

⸻

Pathogenesis of Lemierre Syndrome

The classic progression is:

Acute pharyngitis/tonsillitis

→

Spread into the lateral pharyngeal tissues

→

Internal jugular vein septic thrombophlebitis

→

Fusobacterial bacteremia

→

Septic emboli to distant organs

The lungs are particularly commonly involved.

⸻

Clinical Features of Lemierre Syndrome

Patients may initially have:

• Severe sore throat

• Fever

• Tonsillitis or pharyngitis

They may subsequently develop:

• Persistent or recurrent high fever

• Sepsis

• Unilateral neck pain or swelling

• Tenderness along the internal jugular vein

• Respiratory symptoms from septic pulmonary emboli

⸻

Septic Pulmonary Emboli

Infected thrombus within the internal jugular vein can release septic emboli into the bloodstream.

These frequently travel to the lungs and may produce:

• Multiple pulmonary nodules

• Cavitary lesions

• Pulmonary abscesses

• Pleural infection

• Respiratory distress

This pulmonary pattern is an important clue to Lemierre syndrome.

⸻

Other Metastatic Abscesses

Hematogenous dissemination may also produce abscesses involving:

• Bones

• Joints

• Central nervous system

• Other distant organs

Thus, F. necrophorum can produce a severe metastatic septic illness after an initially localized throat infection.

⸻

Endocarditis

Fusobacterium species can rarely cause infective endocarditis.

Persistent bacteremia or appropriate cardiac findings should prompt consideration of endovascular infection.

⸻

Diagnosis

Diagnosis is established using:

Anaerobic culture

Appropriate specimens may include:

• Blood

• Abscess material

• Pleural fluid

• Deep tissue specimens

Proper anaerobic collection and transport are important for recovery of the organism.

⸻

Diagnosis of Lemierre Syndrome

When Lemierre syndrome is suspected, evaluation typically aims to demonstrate:

Septic thrombosis of the internal jugular vein

along with evidence of infection.

Imaging of the neck can demonstrate the thrombosed vein, while chest imaging may identify septic pulmonary emboli or abscesses.

⸻

Treatment

The source lists:

Metronidazole

and

Penicillin G

as principal antimicrobial options.

Therapy should provide adequate anaerobic coverage and be guided by the clinical syndrome and susceptibility information when available.

⸻

Additional Treatment

Additional agents listed in the source include:

• Clindamycin

• Cefotetan

• Cefoxitin

• Imipenem

• Meropenem

• Chloramphenicol

For severe polymicrobial infection, antimicrobial therapy should also adequately cover other likely pathogens.

⸻

Source Control

Abscess-forming infections frequently require source control in addition to antimicrobial therapy.

This may include:

• Drainage of abscesses

• Surgical debridement

• Management of infected wounds

• Treatment of the underlying dental or abdominal source

⸻

High-Yield Clinical Pattern

Previously healthy adolescent or young adult

Recent pharyngitis

High fever/sepsis

Unilateral neck pain or swelling

Internal jugular vein thrombophlebitis

Multiple septic pulmonary emboli

→ Think Lemierre syndrome due to Fusobacterium necrophorum

⸻

Exam Essentials

Genus: Fusobacterium

Type: Gram-negative bacillus

Oxygen requirement: Anaerobic

Morphology: Often slender/fusiform rods

Normal habitat: Oral and gastrointestinal flora

Usual source: Endogenous infection

Abscesses: Frequently polymicrobial

Major infections: Cervicofacial, pulmonary, abdominal, pelvic, soft-tissue and wound infections

Key species: F. necrophorum

Classic syndrome: Lemierre syndrome

Initial infection: Pharyngitis/tonsillitis

Major vascular complication: Internal jugular vein septic thrombophlebitis

Major metastatic site: Lungs → septic pulmonary emboli/abscesses

Other metastatic sites: Bone and CNS

Diagnosis: Anaerobic culture; imaging is important in Lemierre syndrome

Treatment in source: Metronidazole or penicillin G

Additional agents: Clindamycin, cephamycins, carbapenems

Management principle: Appropriate anaerobic therapy + source control

⸻

Key clinical pearl: The classic association is Fusobacterium necrophorum → Lemierre syndrome: pharyngitis in a young patient followed by sepsis, internal jugular vein septic thrombophlebitis, and septic pulmonary emboli.

Infectious Disease and Microbiology – Fusarium Species

Overview

Fusarium species are filamentous molds with septate hyphae that are widely distributed in the environment. Human infection ranges from localized skin, ocular, bone, and joint disease to severe disseminated fusariosis, particularly in profoundly immunocompromised or neutropenic patients.

A particularly important feature of disseminated Fusarium infection is the combination of fungemia and multiple cutaneous lesions, which can help distinguish it clinically from invasive aspergillosis.

Important Species

Clinically important species traditionally include:

• Fusarium solani

• Fusarium oxysporum

• Fusarium moniliforme

• Other Fusarium species

Several Fusarium organisms are now classified within species complexes, and some older species names have undergone taxonomic revision.

Microbiologic Characteristics

Fusarium species are:

• Filamentous fungi (molds)

• Characterized by septate hyphae

• Hyaline rather than dematiaceous molds

• Widely distributed environmental organisms

They may be found in soil, plants, and organic material.

Epidemiology

Fusarium organisms occur worldwide.

Infection can develop after:

• Traumatic inoculation

• Ocular exposure

• Surgery

• Contamination of indwelling devices

• Severe disruption of host immunity

The clinical pattern depends strongly on the patient’s immune status.

Risk Factors for Invasive Fusariosis

Severe or disseminated infection is particularly associated with:

• Prolonged neutropenia

• Hematologic malignancy

• Hematopoietic stem-cell transplantation

• Profound immunosuppression

• Indwelling vascular catheters

• Major burns

Neutropenia is an especially important risk factor for disseminated disease.

Skin and Subcutaneous Infection

Localized infection may involve the skin and subcutaneous tissues, particularly following traumatic inoculation.

Manifestations may include:

• Nodules

• Ulcerative lesions

• Necrotic lesions

• Cellulitis-like inflammation

In immunocompromised patients, skin lesions may instead represent hematogenous dissemination.

Keratitis

Fusarium is an important cause of fungal keratitis.

Risk factors can include:

• Corneal trauma

• Exposure to plant or soil material

• Contact-lens-related exposure

• Ocular surface abnormalities

Symptoms may include eye pain, redness, photophobia, and impaired vision.

Endophthalmitis

Fusarium species can cause endophthalmitis, a serious infection involving the internal structures of the eye.

Disease may follow ocular trauma or surgery or occur as part of disseminated infection.

Osteomyelitis and Arthritis

Fusarium may cause:

• Osteomyelitis

• Septic arthritis

These infections have been reported particularly following:

Trauma or surgery

Such infections can be difficult to eradicate and may require combined medical and surgical management.

Peritoneal Dialysis-Associated Peritonitis

Fusarium species can rarely cause peritonitis in patients undergoing peritoneal dialysis.

The dialysis catheter may act as a portal of entry or persistent focus of infection.

Catheter-Associated Infection

Catheter-associated Fusarium infection has been reported particularly in:

• Neutropenic patients

• Patients with major burns

Intravascular devices may contribute to persistent fungemia and may require removal when they represent the infection source.

Disseminated Fusariosis

The most serious manifestation is disseminated fusariosis.

It occurs predominantly in severely immunocompromised patients, particularly those with prolonged neutropenia.

Disease can involve:

• Lungs

• Skin

• Bloodstream

• Sinuses

• Eyes

• Central nervous system

• Multiple other organs

Fusarium vs. Aspergillus

Disseminated fusariosis may clinically resemble invasive aspergillosis, but two findings are especially helpful:

Disseminated

Fusarium

→ Pulmonary and systemic invasive disease

→ Cutaneous lesions are relatively common

→ Fungemia/positive blood cultures can occur

Invasive

Aspergillus

→ Similar angioinvasive pulmonary and disseminated disease

→ Cutaneous lesions are generally less prominent

→ Blood cultures are usually negative

Therefore:

Neutropenia + mold infection + skin lesions + positive blood cultures

→ Strongly consider Fusarium

Cutaneous Lesions in Disseminated Disease

Skin lesions are an important clue to disseminated fusariosis.

They may appear as:

• Painful erythematous papules

• Nodules

• Necrotic lesions

• Lesions with central eschar

Biopsy of a skin lesion can provide a relatively accessible method of obtaining tissue for diagnosis.

Fungemia

Unlike many other invasive molds, Fusarium can produce detectable fungemia.

Thus, blood cultures may occasionally grow the organism in disseminated disease.

This is an important exam distinction from Aspergillus.

Diagnosis

Diagnosis is based on:

Identification of fungal elements in tissue biopsy

and

Culture of the fungus

Histopathology helps establish invasive tissue disease, while culture assists with organism identification.

Histopathology

Tissue examination may demonstrate:

Hyaline, septate fungal hyphae

The appearance can resemble Aspergillus, making culture or molecular identification important for definitive differentiation.

Culture

Culture is particularly useful because Fusarium can grow from:

• Tissue specimens

• Skin lesions

• Respiratory specimens

• Blood in disseminated disease

Species identification and antifungal susceptibility information can help guide management because resistance patterns vary.

Treatment

The source notes that clinical data regarding optimal antifungal therapy were limited and describes:

Intravenous amphotericin B

with or without:

Flucytosine

These recommendations reflect the therapeutic approaches available when the source was written.

Modern Treatment Consideration

Treatment of invasive fusariosis is challenging because Fusarium species can demonstrate substantial and variable antifungal resistance.

Management of serious disease therefore depends on:

Species/isolate identification

• ●

Antifungal susceptibility

• ●

Site and extent of infection

• ●

Host immune status

Recovery from neutropenia or improvement of immunosuppression can be critically important to outcome.

Surgical Management

The source emphasizes that surgical removal of operable lesions may be necessary when antifungal therapy alone is insufficient.

Potential interventions include:

• Debridement of infected tissue

• Removal of localized infected lesions

• Management of infected prosthetic material

• Removal of infected catheters when appropriate

Immune Recovery

In disseminated fusariosis, antifungal therapy alone may be insufficient when profound neutropenia persists.

Therefore:

Antifungal therapy + source control + recovery of host immune function

are major components of successful management.

High-Yield Clinical Pattern

Profoundly neutropenic patient

• ●

Pulmonary/systemic mold infection

• ●

Multiple necrotic skin lesions

• ●

Positive blood culture for a mold

→ Think disseminated Fusarium infection

Ocular Pattern

Corneal trauma or environmental exposure

• ●

Painful inflamed cornea

• ●

Septate filamentous fungus

→ Consider Fusarium keratitis

Exam Essentials

Genus: Fusarium

Type: Filamentous mold

Hyphae: Hyaline and septate

Distribution: Worldwide

Localized infections: Skin/subcutaneous infection, keratitis

Deep infections: Endophthalmitis, osteomyelitis, arthritis

Device association: Peritoneal dialysis and intravascular catheters

Major invasive disease: Disseminated fusariosis

Major risk factor: Prolonged neutropenia

Characteristic disseminated finding: Multiple skin lesions

Blood cultures: May be positive, unlike invasive aspergillosis in most cases

Diagnosis: Tissue biopsy + fungal culture

Treatment challenge: Variable antifungal resistance

Additional management: Surgical source control and catheter removal when appropriate

Prognostic factor: Recovery from neutropenia/immune function is extremely important

Key clinical pearl: The classic clue for disseminated fusariosis is a profoundly neutropenic patient with invasive mold disease, multiple necrotic skin lesions, and fungemia. Unlike Aspergillus, Fusarium can frequently produce positive blood cultures, making this distinction especially useful for examinations.